Clinical Trial Update: Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN) [Phase 2]

View source ↗

Summary

A Phase 2 trial of nintedanib plus mFOLFOX6 for previously untreated metastatic esophagogastric adenocarcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagogastric Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Leucovorin (folinic acid)
• Nintedanib (nintedanib)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Esophagogastric Adenocarcinoma, Metastatic Disease | Phase 2 | Status: WITHDRAWN